131 related articles for article (PubMed ID: 36716258)
41. [Clinical case: impact of down-staging after neoadjuvant chemoradiotherapy on the treatment and prognosis of rectal cancer].
Benoist S
Gastroenterol Clin Biol; 2009 Apr; 33(4):289-94. PubMed ID: 19346092
[No Abstract] [Full Text] [Related]
42. Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome?
Geva R; Davidovics H; Soyfer S; Pelles-Avraham S; Klausner JM; Inbar M; Tulchinsky H
Colorectal Dis; 2017 Mar; 19(3):237-242. PubMed ID: 27474791
[TBL] [Abstract][Full Text] [Related]
43. Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer.
Suppiah A; Hunter IA; Cowley J; Garimella V; Cast J; Hartley JE; Monson JR
Colorectal Dis; 2009 Mar; 11(3):249-53. PubMed ID: 18513192
[TBL] [Abstract][Full Text] [Related]
44. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors in patients with complete response of the tumour (ypT0) after neoadjuvant chemoradiotherapy and radical resection of rectal cancer.
Zhang H; Sun G; Zheng K; Lou Z; Gao XH; Meng RG; Furnée EJB; Zhang W
ANZ J Surg; 2021 Apr; 91(4):E190-E195. PubMed ID: 33559307
[TBL] [Abstract][Full Text] [Related]
46. [Application of magnetic resonance in "non-operative treatment" strategy for rectal cancer].
Wang Y; Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):630-634. PubMed ID: 28643307
[TBL] [Abstract][Full Text] [Related]
47. Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes.
Kong JC; Soucisse M; Michael M; Tie J; Ngan SY; Leong T; McCormick J; Warrier SK; Heriot AG
Ann Surg Oncol; 2021 Nov; 28(12):7476-7486. PubMed ID: 33891203
[TBL] [Abstract][Full Text] [Related]
48. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
49. Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer.
Paszt A; Ottlakan A; Abraham S; Simonka Z; Vas M; Maraz A; Szepes Z; Tiszlavicz L; Nyari T; Olah J; Lazar G
Pathol Oncol Res; 2022; 28():1610722. PubMed ID: 36567978
[No Abstract] [Full Text] [Related]
50. [Advances in the prediction of the efficacy and sensitivity of neoadjuvant chemoradiotherapy in rectal cancer].
Ji Q; Li YF; Wu T
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):392-397. PubMed ID: 31054555
[TBL] [Abstract][Full Text] [Related]
51. Changing the Treatment Paradigm for Locally Advanced Rectal Cancer.
Dossa F; Baxter NN
N Engl J Med; 2023 Jul; 389(4):375-377. PubMed ID: 37494491
[No Abstract] [Full Text] [Related]
52. Clinical predictors of response to chemoradiotherapy for rectal cancer as an aid to organ preservation.
Fischer J; Eglinton TW; Frizelle FA
ANZ J Surg; 2021 Jun; 91(6):1190-1195. PubMed ID: 33404195
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemoradiotherapy for rectal cancer: how important is tumour regression?
McCoy MJ; Hemmings C; Hillery S; Penter C; Bulsara MK; Zeps N; Platell CF
ANZ J Surg; 2017 Dec; 87(12):E233-E239. PubMed ID: 26631340
[TBL] [Abstract][Full Text] [Related]
54. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
55. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.
MacGregor TP; Maughan TS; Sharma RA
J Clin Pathol; 2012 Oct; 65(10):867-71. PubMed ID: 22734005
[TBL] [Abstract][Full Text] [Related]
56. Limited accuracy of DCE-MRI in identification of pathological complete responders after chemoradiotherapy treatment for rectal cancer.
Gollub MJ; Tong T; Weiser M; Zheng J; Gonen M; Zakian KL
Eur Radiol; 2017 Apr; 27(4):1605-1612. PubMed ID: 27436029
[TBL] [Abstract][Full Text] [Related]
57. Magnetic resonance imaging of rectal cancer.
Dewhurst CE; Mortele KJ
Radiol Clin North Am; 2013 Jan; 51(1):121-31. PubMed ID: 23182512
[TBL] [Abstract][Full Text] [Related]
58. Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
Kato T; Fujii T; Ide M; Takada T; Sutoh T; Morita H; Yajima R; Yamaguchi S; Tsutsumi S; Asao T; Oyama T; Kuwano H
Anticancer Res; 2014 Jun; 34(6):3141-6. PubMed ID: 24922685
[TBL] [Abstract][Full Text] [Related]
59. Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer.
Elmi A; Hedgire SS; Covarrubias D; Abtahi SM; Hahn PF; Harisinghani M
Clin Radiol; 2013 Oct; 68(10):e524-31. PubMed ID: 23830776
[TBL] [Abstract][Full Text] [Related]
60. Parameters for Predicting Tumour Response Following Neoadjuvant Chemoradiotherapy for Patients with Rectal Cancer.
Bengulescu I; Radu P; Iorga C; Bratucu M; Pasnicu C; Garofil D; Popa F; Strambu V
Chirurgia (Bucur); 2020; 115(3):365-372. PubMed ID: 32614292
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
